Recent News

• 03.18.2026 - Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe
• 03.05.2026 - Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain
• 02.26.2026 - Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy
• 02.18.2026 - Vietnam Approves Biomerica’s EZ Detect™ for Nationwide Distribution
• 01.14.2026 - Biomerica Reports Second Quarter Fiscal 2026 Financial Results
• 12.23.2025 - Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test
• 12.11.2025 - Egyptian Drug Authority Authorizes Biomerica’s Complete Screening Test Portfolio
• 11.25.2025 - Biomerica’s inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS
• 11.06.2025 - Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand

Recent Filings

• 02.27.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 01.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.14.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 12.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.16.2025 - 8-K Current report
• 10.23.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material